SCHEMBL6357878

SCHEMBL6357878

CCCS(=O)(=O)NC1CCCCC1(F)c1ccc(OCCNC(C)=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
MTNR1A P48039 3/20 0.42
MTNR1B P49286 3/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
TSHR P16473 2/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.37
ACACB O00763 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
EPHX2 P34913 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346463 0.97 ALDH1A1 (0.45) ALDH1A1MTNR1AMTNR1BMEN1KMT2A
SCHEMBL6345791 0.89 ALDH1A1 (0.44) ALDH1A1MTNR1AMTNR1BMEN1KMT2A
SCHEMBL7092690 0.88 SLC6A9 (0.45) ALDH1A1MEN1KMT2ATSHRCYP1A2
SCHEMBL6350038 0.87 MTNR1A (0.42) ALDH1A1MTNR1AMTNR1BMEN1KMT2A
SCHEMBL6344448 0.87 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ATSHRCYP1A2
SCHEMBL6355740 0.86 ALDH1A1 (0.45) ALDH1A1MTNR1AMTNR1BMEN1KMT2A
SCHEMBL6347185 0.85 SLC6A9 (0.45) ALDH1A1MEN1KMT2ATSHRCYP1A2
SCHEMBL6346460 0.84 MTNR1A (0.43) ALDH1A1MTNR1AMTNR1BMEN1KMT2A
SCHEMBL6354375 0.83 ALDH1A1 (0.43) ALDH1A1MEN1KMT2ATSHRCYP1A2
SCHEMBL6347843 0.82 SLC6A4 (0.43) ALDH1A1L3MBTL1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 ALDH1A1 642/4885MTNR1A 212/4885MTNR1B 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.